{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:44:37Z","timestamp":1791989077375,"version":"4.4.0"},"reference-count":57,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Systemic Janus kinase inhibitors (JAKIs) have markedly advanced the therapeutic landscape for alopecia areata (AA). Although baricitinib and ritlecitinib are approved in the United States (US) and Europe, and deuruxolitinib in the US for severe AA, the lack of head\u2010to\u2010head randomized controlled trials (RCTs) limits evidence\u2010based prescribing decisions. Moreover, prior meta\u2010analyses excluded data on certain oral JAKIs or incorporated findings from agents and dosing regimens that were abandoned, investigational, clinically ineffective, or associated with unacceptable safety profiles. To compare the efficacy of oral JAKIs, limited to FDA, EMA, or MHRA approved drugs and doses\u2014baricitinib (2 and 4\u2009mg QD), ritlecitinib (50\u2009mg QD), and deuruxolitinib (8\u2009mg BID)\u2014for severe AA, using advanced indirect comparison methodologies. A systematic review was performed following PRISMA 2020 guidelines (CRD420251116775). Bayesian network meta\u2010analysis (NMA) synthesized data from RCTs reporting Week 24 outcomes on Severity of Alopecia Tool (SALT) \u2264\u200910 and SALT \u2264\u200920 thresholds. Multilevel network meta\u2010regression (ML\u2010NMR) evaluated heterogeneity and adjusted for baseline imbalances. Additionally, unanchored matching\u2010adjusted indirect comparisons (MAIC) were conducted using individual patient\u2010level data from THRIVE trials. Surface under the cumulative ranking (SUCRA) values were calculated to rank treatments. Seven RCTs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094560 participants) were included. Deuruxolitinib 8\u2009mg significantly outperformed baricitinib 2 and 4\u2009mg on both SALT endpoints. Differences with ritlecitinib 50\u2009mg were directionally favorable for deuruxolitinib but not statistically significant in NMA and ML\u2010NMR models. MAICs confirmed superior odds for deuruxolitinib versus baricitinib 2\u2009mg (OR\u2009=\u200971.55) and ritlecitinib (OR\u2009=\u200918.27) for SALT \u2264\u200920. SUCRA rankings also consistently favored deuruxolitinib. Among approved oral JAKIs, deuruxolitinib 8\u2009mg shows the highest short\u2010term efficacy for severe AA. These findings provide preliminary evidence to guide treatment decisions but should be interpreted as exploratory pending confirmation.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.17959","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:25:25Z","timestamp":1760167525000},"page":"1395-1407","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta\u2010Analysis and Matching\u2010Adjusted Indirect Comparison"],"prefix":"10.1111","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7345-2856","authenticated-orcid":false,"given":"Arya","family":"Babul","sequence":"first","affiliation":[{"name":"Society for Awareness of Tropical Diseases  Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devina","family":"Mehta","sequence":"additional","affiliation":[{"name":"Thomas Dermatology  Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-3311","authenticated-orcid":false,"given":"Yssra","family":"Soliman","sequence":"additional","affiliation":[{"name":"Thomas Dermatology  Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momina","family":"Hussain","sequence":"additional","affiliation":[{"name":"Genomics Department Chinese Academy of Tropical Agriculture Sciences  Sanya China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Babul","sequence":"additional","affiliation":[{"name":"Quadra Therapeutics  Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15842"},{"issue":"1","key":"e_1_2_9_3_1","article-title":"Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities","volume":"17","author":"Abarca Y. A.","year":"2025","journal-title":"Cureus"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1103442"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2025.04.013"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20211"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2024.2409660"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2348062"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243556"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14815"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00808-1"},{"issue":"1","key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1515\/medgen-2023-2004","article-title":"Recent Advances in the Genetics of Alopecia Areata","volume":"35","author":"Buket Basmanav F.","year":"2023","journal-title":"Medizinische Genetik: Mitteilungsblatt Des Berufsverbandes Medizinische Genetik eV"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/348546"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70182"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110334"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S172638"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2024.10.001"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15838"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15822"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae385"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19768"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19812"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.004"},{"key":"e_1_2_9_25_1","article-title":"Treatments for Alopecia Areata: A Network Meta\u2010Analysis","volume":"10","author":"Mateos\u2010Haro M.","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.267"},{"key":"e_1_2_9_27_1","volume-title":"Baricitinib","author":"Ahmad A. Z. M.","year":"2024"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03182-y"},{"key":"e_1_2_9_29_1","first-page":"1621","volume-title":"Efficacy and Safety of PF\u201006651600 (Ritlecitinib), A Novel JAK3\/TEC Inhibitor, in Patients With Moderate\u2010To\u2010Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis & Rheumatology","author":"Robinson M. F.","year":"2020"},{"key":"e_1_2_9_30_1","unstructured":"\u201c(Deuruxolitinib) L. NDA\/BLA Multi\u2010Disciplinary Review and Evaluation APPLICATION NUMBER: 217900Orig1s000 \u201dCenter for Drug Evaluation and Research FDA 2024."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_452_22"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1372810"},{"key":"e_1_2_9_33_1","first-page":"1","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page M. J.","year":"2021","journal-title":"BMJ"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","unstructured":"D. M.Phillippo \u201cMultinma: Bayesian Network Meta\u2010Analysis of Individual and Aggregate Data \u201d2020.","DOI":"10.32614\/CRAN.package.multinma"},{"key":"e_1_2_9_36_1","volume-title":"Heterogeneity: Subgroups, Meta\u2010Regression, Bias and Bias\u2010Adjustment","author":"Dias S.","year":"2012"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/rssa.12579"},{"key":"e_1_2_9_38_1","doi-asserted-by":"crossref","unstructured":"D. M.Phillippo S.Dias A.Ades andN. J.Welton \u201cMultilevel Network Meta\u2010Regression for General Likelihoods: Synthesis of Individual and Aggregate Data With Applications to Survival Analysis \u201darXiv preprint arXiv:240112640 2024.","DOI":"10.1093\/jrsssa\/qnaf169"},{"key":"e_1_2_9_39_1","unstructured":"Team RC \u201cA Language and Environment for Statistical Computing \u201d2023 R Foundation for Statistical Computing."},{"key":"e_1_2_9_40_1","unstructured":"Team SD \u201cReference Manual. Version 236 \u201d2023."},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2734"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.045"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2"},{"key":"e_1_2_9_47_1","doi-asserted-by":"crossref","unstructured":"B. K. S.King N. A.Mesinkovska P.Mirmirani et\u00a0al. \u201cOptimization of Deuruxolitinib Dosing in Adult Patients With Alopecia Areata: Results From a Randomized Parallel\u2010Group Multicenter Phase 2 Trial \u201dAmerican Academy of Dermatology Annual Meeting 2025.","DOI":"10.1016\/j.jaad.2025.05.1032"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.12.008"},{"key":"e_1_2_9_49_1","unstructured":"M. Q. V.Yu E.Li J.Nelson andC.Colavincenzo \u201cRational and Efficacy of Janus Kinase Inhibitor Switching for Alopecia Areata \u201dAmerican Academy of Dermatology Annual Meeting 2025."},{"key":"e_1_2_9_50_1","doi-asserted-by":"crossref","unstructured":"A. S. D.Martin S. M.Mack K.Kelley andM.Senna \u201cSwitching Between Janus Kinase Inhibitors for Treatment of Alopecia Areata \u201dPresentation American Academy of Dermatology Annual Meeting 2025.","DOI":"10.1016\/j.jaad.2025.05.344"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20372"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1152513"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2004.00462.x"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-013-0020-5"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S417180"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2014.01.013"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.677419"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2012.18.7.527"}],"updated-by":[{"DOI":"10.1111\/1346-8138.70437","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000}}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.17959","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:49:35Z","timestamp":1791985775000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/1346-8138.17959"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17959","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"2025-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}